
Abivax SA (ABVX) Stock Forecast & Price Target
Abivax SA (ABVX) Analyst Ratings
Bulls say
Abivax SA is currently conducting Phase 3 clinical trials for obefazimod, which has demonstrated statistically significant improvements in clinical remission for patients with ulcerative colitis, particularly in those with inadequate responses to advanced treatments. The growing market for ulcerative colitis therapies, projected to increase from $9.2 billion in 2025 to $21.2 billion by 2032, presents a substantial opportunity for the company, further underscored by the successful meeting of EMA co-primary endpoints in its studies. Additionally, the rapid therapeutic effect of obefazimod and the expertise of Abivax's management team contribute to a strong outlook for the company in an established market with significant unmet needs.
Bears say
Abivax SA's stock faces a negative outlook primarily due to the disappointing translation of initial induction results into meaningful maintenance efficacy, raising concerns reminiscent of previous failures from competitors in the sector. The company's low ~3% placebo response rate in its induction trial further undermines confidence in the robustness and real-world applicability of its data. Additionally, the low efficacy bar set by previous oral therapies, which have struggled with efficacy and safety, does not provide a strong foundation for obefazimod's commercial success in a competitive and challenging therapeutic landscape.
This aggregate rating is based on analysts' research of Abivax SA and is not a guaranteed prediction by Public.com or investment advice.
Abivax SA (ABVX) Analyst Forecast & Price Prediction
Start investing in Abivax SA (ABVX)
Order type
Buy in
Order amount
Est. shares
0 shares